Ann: Trading Halt, page-36

Just a few things to keep in mind so we can relax and enjoy our weekends with a proper sense of perspective:

- This 008 trial has zero bearing on our main pivotal Phase III trial (002), which will ultimately determine whether we get a label or not

- 008 is an investigative trial which will primarily aim to shed some light on what happens *inside the knee* after Zilosul is injected into your arse

- There is already data showing Zilosul's impact on these same biomarkers from OA 2b trial, and Ross River Virus trial in serum, and it would be both shocking and mystifying to all involved if nothing happened in the synovium of the knee considering that's where the positive outcomes in hundreds of patients (pain, function etc) have all been witnessed

- If 008 in it's entirety is to produce Earth-shatteringly positive indications of how Zilosul appears to modify OA - there may be ZERO evidence of this at Day 56 (this means that 008 could feasibly FAIL it's primary endpoint [spoiler: it won't], but still ultimately be a roaring success after 6 & 12 months data is all in, dependent on what is shown)

- In the same vein, nothing that Day 56 shows can really be relied upon to extrapolate out to 6 & 12 months (positive, as well as negative)

In short, when we get the results on Tuesday, any conclusions which you or 'the market' attempts to draw is akin to calling the winner of a footy match after the first 5 minutes. Therefore, any conclusions you are drawing TODAY are just plain silly. Better overall to think of this trial (especially it's 6- and 12-month data) as nothing more or less than free hit at some evidence to further our understanding of the science behind Zilosul's impact on OA, to support future (confirmatory) trials, and to wave in front of potential Big Pharma partners to ramp up FOMO and maximise any eventual deals we get.